One Step Closer to LAMA2-RD Clinical Trials: Modalis Therapeutics
Modalis Therapeutics program for LAMA2-RD gene therapy granted Rare Pediatric Disease Designation by FDA.
top of page
Search
Rachel Alvarez
Jun 52 min read
Omigapil Publication Now Available
Long-awaited publication about the Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy now published.
Cure CMD
Apr 4, 201811 min read
Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Cong
Please see the end of this article for Frequently Asked Questions - CALLISTO Phase 1 Clinical Trial Pratteln, Switzerland, April 5, 2018...
bottom of page